Report cover image

Cytomegalovirus Infection Treatment Market - 2023-2031

Publisher DataM Intelligence 4Market Research LLP
Published Nov 26, 2025
Length 210 Pages
SKU # DTAM21130892

Description

Cytomegalovirus Infection Treatment Market Overview:
The Cytomegalovirus Infection Treatment Market was valued at US$ 516.36 million in 2023 and is anticipated to reach US$ 858.65 million by 2031, at a CAGR of 0.067 from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Cytomegalovirus Infection Treatment Market.

This report delivers a comprehensive overview of the Cytomegalovirus Infection Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cytomegalovirus Infection Treatment Market. The Cytomegalovirus Infection Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

Cytomegalovirus Infection Treatment Market Scope:
By Drug Type
• Cytovene
• Valcyte
• Foscarnet
• Vistide
• Others

By Application
• Stem Cell Transplantation
• Organ Transplantation
• Congenital CMV infection
• Others

By Infection
• Retinitis
• Pneumonia
• Esophagitis
• Colitis
• Others

By Diagnosis Test
• Serologic Test
• Polymerase Chain Reaction (PCR) Test
• Others

By Route of Administration
• Oral
• Intravenous

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

By End-User
• Hospitals
• Specialty Clinics
• Homecare
• Others

Key Players
• Merck & Co., Inc
• F. Hoffmann-La Roche Ltd
• Fresenius Kabi Canada
• GSK Plc
• AiCuris Anti-infective Cures AG
• Chimerix, Inc
• Abbott
• Bio-Rad Laboratories, Inc
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd

Major Highlights
This report delivers a comprehensive overview of the Cytomegalovirus Infection Treatment Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Cytomegalovirus Infection Treatment Market. The Cytomegalovirus Infection Treatment Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2023–2031.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
South America (Colombia, Brazil, Argentina, Rest of South America)
Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification
Increase Your Customer Base by 3X using our Partner Identification tool
Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?
• Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
• Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
• White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
• Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
• Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
• Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

210 Pages
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Type
3.2. Snippet by Application
3.3. Snippet by Infection
3.4. Snippet by Diagnosis Test
3.5. Snippet by Route of Administration
3.6. Snippet by Distribution Channel
3.7. Snippet by End-User
3.8. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Viral Infections
4.1.1.2. Rising Prevalence of CMV Retinitis and Congenital CMV infection
4.1.1.3. Growing Government Initiatives for Creating Awareness Regarding Treatments
4.1.1.4. The Growing Demand for Personalized Medicine
4.1.2. Restraints
4.1.2.1. Adverse Effects and Risks Related to Cytomegalovirus Drugs
4.1.2.2. High Cost Associated with the Treatment
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Drug Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
7.1.2. Market Attractiveness Index, By Drug Type
7.2. Cytovene*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Valcyte
7.4. Foscarnet
7.5. Vistide
7.6. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Stem Cell Transplantation*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Organ Transplantation
8.4. Congenital CMV infection
8.5. Others
9. By Infection
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
9.1.2. Market Attractiveness Index, By Infection
9.2. Retinitis*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Pneumonia
9.4. Esophagitis
9.5. Colitis
9.6. Others
10. By Diagnosis Test
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
10.1.2. Market Attractiveness Index, By Diagnosis Test
10.2. Serologic Test*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Polymerase Chain Reaction (PCR) Test
10.4. Others
11. By Route of Administration
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
11.1.2. Market Attractiveness Index, By Route of Administration
11.2. Oral*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Intravenous
12. By Distribution Channel
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.1.2. Market Attractiveness Index, By Distribution Channel
12.2. Hospital Pharmacy*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Retail Pharmacy
12.4. Online Pharmacy
12.5. Others
13. By End-User
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.1.2. Market Attractiveness Index, By End-User
13.2. Hospitals*
13.2.1. Introduction
13.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
13.3. Specialty Clinics
13.4. Homecare
13.5. Others
14. By Region
14.1. Introduction
14.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
14.1.2. Market Attractiveness Index, By Region
14.2. North America
14.2.1. Introduction
14.2.2. Key Region-Specific Dynamics
14.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.2.10.1. U.S.
14.2.10.2. Canada
14.2.10.3. Mexico
14.3. Europe
14.3.1. Introduction
14.3.2. Key Region-Specific Dynamics
14.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.3.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.3.10.1. Germany
14.3.10.2. UK
14.3.10.3. France
14.3.10.4. Italy
14.3.10.5. Spain
14.3.10.6. Rest of Europe
14.4. South America
14.4.1. Introduction
14.4.2. Key Region-Specific Dynamics
14.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.4.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.4.10.1. Brazil
14.4.10.2. Argentina
14.4.10.3. Rest of South America
14.5. Asia-Pacific
14.5.1. Introduction
14.5.2. Key Region-Specific Dynamics
14.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
14.5.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
14.5.10.1. China
14.5.10.2. India
14.5.10.3. Japan
14.5.10.4. South Korea
14.5.10.5. Rest of Asia-Pacific
14.6. Middle East and Africa
14.6.1. Introduction
14.6.2. Key Region-Specific Dynamics
14.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
14.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
14.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection
14.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diagnosis Test
14.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
14.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
14.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
15. Competitive Landscape
15.1. Competitive Scenario
15.2. Market Positioning/Share Analysis
15.3. Mergers and Acquisitions Analysis
16. Company Profiles
16.1. Merck & Co., Inc *
16.1.1. Company Overview
16.1.2. Product Portfolio and Description
16.1.3. Financial Overview
16.1.4. Key Developments
16.2. F. Hoffmann-La Roche Ltd
16.3. Fresenius Kabi Canada
16.4. GSK Plc
16.5. AiCuris Anti-infective Cures AG
16.6. Chimerix, Inc
16.7. Abbott
16.8. Bio-Rad Laboratories, Inc
16.9. Takeda Pharmaceutical Company Limited
16.10. Teva Pharmaceutical Industries Ltd (LIST NOT EXHAUSTIVE)
17. Appendix
17.1. About Us and Services
17.2. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us